Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 11/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17110477 | 0.86 | NTRK1 (0.50) | NTRK1KMO | |
| SCHEMBL29633186 | 0.84 | NTRK1 (0.53) | NTRK1KMO | |
| SCHEMBL18748544 | 0.82 | NTRK1 (0.50) | NTRK1KMOSLC6A7CYP1A2CYP3A4 | |
| SCHEMBL17110505 | 0.81 | NOTUM (0.58) | NTRK1ALOX15 | |
| SCHEMBL31542017 | 0.76 | NOTUM (0.42) | KCNQ3KCNQ2KCNE1KCNQ1CYP1A2 | |
| SCHEMBL2680326 | 0.76 | NOTUM (0.42) | KCNQ3KCNQ2KCNE1KCNQ1CYP1A2 | |
| SCHEMBL30892335 | 0.74 | GLA (0.45) | KCNQ3KCNQ2KCNE1KCNQ1CYP1A2 | |
| SCHEMBL278277 | 0.74 | GLA (0.45) | KCNQ3KCNQ2KCNE1KCNQ1CYP1A2 | |
| SCHEMBL8151708 | 0.73 | CES2 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1CYP1A2 | |
| SCHEMBL30308280 | 0.73 | KIF11 (0.56) | KCNQ3KCNQ2KCNE1KCNQ1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122344-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3122345-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3122346-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10556900-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180105518-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9914736-B2 | TrKA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9862707-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9862716-B2 | TRKA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9815846-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170158698-A1 | TrKA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-3122343-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-3122345-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-3122346-A2 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2016161572-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2015148344-A2 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148350-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148373-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015143652-A1 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015143654-A1 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015143653-A1 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105518-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NTRK2, NGF | NTRK1 5/4885KMO 282/4885SLC6A7 4436/4885 |
| US-20170158698-A1 | TrKA Kinase Inhibitors, Compositions and Methods Thereof | NGFR, NGF, NTRK2 | NTRK1 4/4885KMO 1717/4885SLC6A7 4077/4885 |
| US-10556900-B2 | TrkA kinase inhibitors, compositions and methods thereof | NGFR, NTRK2, NGF | NTRK1 5/4885KMO 282/4885SLC6A7 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.